Jasper Therapeutics will present preliminary data from the BEACON study of briquilimab, which could enhance the visibility and interest in their novel antibody therapy. The inclusion of Dr. Thomas B.
Rezolute, Inc. Announces Late-Breaking Presentation of Phase 3 Study Data for Ersodetug at ENDO 2025
Rezolute, Inc., a company focused on treating hypoglycemia caused by hyperinsulinism, announced that its abstract for a Phase 3 study of its drug Ersodetug will be presented at ENDO 2025 in San ...
– Substantial and durable reductions in convulsive seizure frequency observed in patients treated with 2 or 3 doses of 70mg followed by 45mg maintenance dosing on top of the best available ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results